Advertisement
Australia markets closed
  • ALL ORDS

    8,022.70
    +28.50 (+0.36%)
     
  • ASX 200

    7,749.00
    +27.40 (+0.35%)
     
  • AUD/USD

    0.6604
    -0.0017 (-0.26%)
     
  • OIL

    78.20
    -1.06 (-1.34%)
     
  • GOLD

    2,366.90
    +26.60 (+1.14%)
     
  • Bitcoin AUD

    92,012.69
    -3,039.69 (-3.20%)
     
  • CMC Crypto 200

    1,259.37
    -98.64 (-7.27%)
     
  • AUD/EUR

    0.6128
    -0.0010 (-0.16%)
     
  • AUD/NZD

    1.0963
    -0.0006 (-0.05%)
     
  • NZX 50

    11,755.17
    +8.59 (+0.07%)
     
  • NASDAQ

    18,161.18
    +47.72 (+0.26%)
     
  • FTSE

    8,433.76
    +52.41 (+0.63%)
     
  • Dow Jones

    39,512.84
    +125.08 (+0.32%)
     
  • DAX

    18,772.85
    +86.25 (+0.46%)
     
  • Hang Seng

    18,963.68
    +425.87 (+2.30%)
     
  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     

Company News For Nov 18, 2019

  • Shares of Applied Materials, Inc. AMAT rose nearly 9% after the company reported fiscal fourth-quarter 2019 non-GAAP earnings of 80 cents per share, beating the Zacks Consensus Estimate by 4 cents

  • Shares of Digi International Inc. DGII rose nearly 15% after the company reported  third-quarter 2019 earnings of $0.18 per share, surpassing the Zacks Consensus Estimate of $0.07

  • Shares of resTORbio, Inc. TORC plunged 86.3% after the company reported that its Phase 3 PROTECTOR 1 trial of RTB101 was unsuccessful

  • Shares of Limbach Holdings, Inc. LMB fell 35.1% after the company reported third-quarter 2019 earnings of $0.10 per share, missing the Zacks Consensus Estimate of $0.23


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Digi International Inc. (DGII) : Free Stock Analysis Report
 
Applied Materials, Inc. (AMAT) : Free Stock Analysis Report
 
resTORbio, Inc. (TORC) : Free Stock Analysis Report
 
Limbach Holdings, Inc. (LMB) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research